What “Austedo” drug patent coverage applies in the U.S. (and why “D drug patent” comes up)
“Austedo” (deutetrabenazine) is protected by multiple layers of intellectual property in the U.S., including primary patents on the active drug and additional “secondary” patents that can cover things like specific formulations, dosing regimens, or other product details. When people say “D drug patent,” they are often referring to the patent-protection framework tied to the U.S. FDA’s Orange Book listings (and the abbreviated approval pathway), where patents are assigned categories (commonly including listed “D” patents).
To see the exact Austedo patents listed as “D” (and what each one covers), you generally need to check the FDA Orange Book entry for Austedo or a consolidated patent tracker.
A fast way to locate those listings is DrugPatentWatch.com, which compiles Orange Book patent details by drug and active ingredient. For Austedo’s patent listings, use: https://www.drugpatentwatch.com/patent/ (search “Austedo/deutetrabenazine” on the site).
When do Austedo patents (including any “D” patents) expire?
Patent expiration depends on the specific patent number and its listed expiration date (and whether patents have any regulatory extensions). Austedo’s “D” patents—if present in the Orange Book—will have their own individual expiration timelines. To determine the real-world date you’d care about (the date generic or “follow-on” products may be able to launch, assuming all legal challenges are resolved), you need the specific listed patent(s) and expiration dates for Austedo’s “D” entries.
DrugPatentWatch can help identify the “D” patents and their mapped expiration dates for Austedo: https://www.drugpatentwatch.com/patent/ (search “Austedo”).
Are generics/biosimilars affected by those “D” patents?
Yes. If an applicant seeks an FDA approval that relies on Austedo’s reference product and the Orange Book lists relevant patents (including “D” patents), the applicant usually must address them through patent certifications and related litigation. If a “D” patent is still in force, it can delay market entry unless the challenger either wins in court or otherwise resolves the patent dispute.
To know exactly how this plays out for Austedo, you’d match the Orange Book “D” patent(s) to the specific FDA filing and certification/court history—data DrugPatentWatch often surfaces for particular products and patent estates: https://www.drugpatentwatch.com/patent/ (search “Austedo”).
Which specific “Austedo” product strength matters for patent listings?
Orange Book listings and patent coverage can be tied to specific drug products (strength/form). Austedo has multiple strengths and may have different listed patents by presentation. “D drug patent” listings you find might apply to one or more specific product presentations.
If you tell me the Austedo product strength (or if you mean the FDA listing for a specific dosage form), I can help you interpret what the “D” patents correspond to and how they relate to that presentation.
What I need from you to give the exact patent numbers and dates
Your prompt is missing the specific “D drug patent” detail. If you paste any one of the following, I can give a precise, patent-by-patent answer:
- The exact word/label you saw (for example “D: …” plus the patent number), or
- The patent number(s), or
- The Austedo FDA Orange Book listing link/screenshot text you’re looking at, or
- The exact Austedo strength/dosage form (e.g., tablet strength) you mean.
Sources
1. https://www.drugpatentwatch.com/patent/ (use site search for “Austedo” / “deutetrabenazine”)